Primary tumors of the lung: should we consider thermal ablation as a valid therapeutic option?

Palussière, Jean; Catena, Vittorio; Lagarde, P.; Cousin, Sophie; Cabart, Mathilde; Buy, Xavier; Chomy, François

doi:10.1080/02656736.2019.1647351

Cited by 18 publications

(13 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Alveolar haemorrhage with or without accompanying haemoptysis is also usually self‐limiting; cryoablation is associated with a higher haemoptysis rate than RFA or MWA 9,33 . CTCAE grade 3 and 4 complications range below 3% in studies originating from large centres with high ablation numbers, and include bronchopleural fistula (Figure 5), aseptic pleuritis, pneumonia, abscess, pleural seeding and nerve damage 31,34,35 . Air embolism and development of pulmonary artery aneurysm are reported at less than 0.3% 36…”

Section: Cryoablationmentioning

confidence: 99%

Current trends in image‐guided chest interventions

et al. 2022

View full text Add to dashboard Cite

Interventional radiology (IR) is a rapidly expanding medical subspecialty and refers to a range of image-guided procedural techniques. The image guidance allows real-time visualization and precision placement of a needle, catheter, wire and device to deep body structures through small incisions. Advantages include reduced risks, faster recovery and shorter hospital stays, lower costs and less patient discomfort. The range of chest interventional procedures keeps on expanding due to improved imaging facilities, better percutaneous assess devices and advancing ablation and embolization techniques. These advances permit procedures to be undertaken safely, simultaneously and effectively, hence escalating the role of IR in the treatment of chest disorders. This review article aims to cover the latest developments in some image-guided techniques of the chest, including thermal ablation therapy of lung malignancy, targeted therapy of pulmonary embolism, angioplasty and stenting of mediastinal venous/superior vena cava occlusion, pulmonary arteriovenous malformation treatment and bronchial artery embolization for haemoptysis.

show abstract

Section: Cryoablationmentioning

confidence: 99%

Current trends in image‐guided chest interventions

et al. 2022

View full text Add to dashboard Cite

show abstract

“…102 Both pre-clinical and clinical studies suggest potential for augmentation of efficacy of immunotherapy in advanced NSCLC. [103][104][105] Further studies may support a role for combined tumour ablation with immune checkpoint blockade, 106,107 extending the role for bronchoscopic ablation to include patients with locally advanced or even metastatic NSCLC. Ablation could even be delivered at the time of EBUS-directed diagnostic sampling, following onsite cytological diagnosis of peripheral lesions, 108 thereby reducing the number of procedures that patients require.…”

Section: So… Are We Ready For Prime Time?mentioning

confidence: 99%

Bronchoscopic treatments for early‐stage peripheral lung cancer: Are we ready for prime time?

Steinfort

Herth

2020

Respirology

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer-related death worldwide and surgical lobectomy remains the preferred therapy for patients with early-stage NSCLC. Medical comorbidities and advanced age preclude resection in many patients and minimally invasive ablative therapies are needed for treatment. Stereotactic ablative radiation is established as an effective modality in this patient group, although may be contraindicated in some patients with prior radiation exposure, comorbidities or centrally positioned tumours. Percutaneous ablative methods are available, although are frequently associated with significant complications. Numerous endoscopic ablative techniques are under evaluation. With a more favourable safety profile and the ability to provide diagnosis and staging information potentially within a single procedure, there is a strong rationale for development of bronchoscopic ablative modalities. In the following article, the authors aim to explore the role bronchoscopic ablation may play in treatment of peripheral lung tumours, and to describe a pathway to establishing these modalities as part of routine care. The current status of several bronchoscopic ablative options is discussed in detail.

show abstract

“…In addition, another study also mentioned that MWA combined with chemotherapy is superior to chemotherapy alone in progression-free survival (PFS) and overall survival (OS) [10]. Although there have been a lot of comparisons between RFA and MWA in different treatment schemes and different tumor types, the clinical efficacy of thermal ablation combined with systemic chemotherapy in the treatment of lung cancer is still uncertain [11]. Therefore, we aimed to study the clinical efficacy of thermal ablation (RFA and MWA) combined with systemic chemotherapy in treating patients with lung cancer and to provide a reference for the clinical application of thermal ablation techniques in lung cancer treatment.…”

Section: Introductionmentioning

confidence: 99%

Clinical efficacy of systemic chemotherapy combined with radiofrequency ablation and microwave ablation for lung cancer: a comparative study

Song

Lü

et al. 2021

International Journal of Hyperthermia

View full text Add to dashboard Cite

Objective: Local thermal ablation, a minimally invasive technique, has been widely used in clinical treatment of lung cancer. This study aimed to discuss the clinical efficacy of systemic chemotherapy combined with radiofrequency ablation (RFA) versus systemic chemotherapy combined with microwave ablation (MWA) in treating lung cancer. Methods: A retrospective analysis involving 124 lung cancer patients, who received RFA (n ¼ 68) and MWA (n ¼ 56) combined with systemic chemotherapy in Cangzhou People's Hospital from August 2017 to December 2019, was conducted. Before comparative analysis for therapeutic efficacy, the two groups of patients were matched with propensity score matching method at a ratio of 1:1. Indicators including progression-free survival (PFS), overall survival (OS), short-term efficacy, tumor marker level, local tumor control rate, and postoperative complications were comparatively analyzed. Results: There was no statistical difference in disease control rate and objective response rate (90.6% and 78.1% vs 93.8% and 84.4%) between RFA group and MWA group. The incidence of complications was 12.5% in RFA group and 18.8% in MWA group with no statistically significant difference. In addition, the local tumor control rate in MWA group (90.6%) was significantly higher than that in RFA group (78.1%). Regarding survival, a statistically significant difference was observed in median PFS of RFA and MWA groups (9.2 months vs 10.4 months, p < 0.05), while OS in two groups slightly varied. Conclusion: MWA was superior to RFA over local tumor control rate and PFS and showed great potential in lung cancer ablation treatment.

show abstract

Primary tumors of the lung: should we consider thermal ablation as a valid therapeutic option?

Cited by 18 publications

References 50 publications

Current trends in image‐guided chest interventions

Current trends in image‐guided chest interventions

Bronchoscopic treatments for early‐stage peripheral lung cancer: Are we ready for prime time?

Clinical efficacy of systemic chemotherapy combined with radiofrequency ablation and microwave ablation for lung cancer: a comparative study

Contact Info

Product

Resources

About